Public health. A sound rationale needed for phase III HIV-1 vaccine trials

Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620.
No abstract available

MeSH terms

  • AIDS Vaccines / immunology*
  • Clinical Trials, Phase III as Topic* / economics
  • Costs and Cost Analysis
  • HIV Envelope Protein gp120 / immunology*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control
  • HIV Infections / therapy
  • HIV-1 / immunology*
  • Humans
  • Immunization Schedule
  • Immunization, Secondary
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Helper-Inducer / immunology
  • Thailand
  • United States
  • Vaccines, Synthetic / immunology

Substances

  • AIDS Vaccines
  • HIV Envelope Protein gp120
  • Vaccines, Synthetic